What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?Benzinga • 06/17/24
Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for SoticlestatGlobeNewsWire • 06/17/24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsGlobeNewsWire • 05/14/24
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/24
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/26/24
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/04/24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/08/24
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/28/24
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)GlobeNewsWire • 12/01/23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 11/03/23
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026GlobeNewsWire • 10/18/23
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023GlobeNewsWire • 09/26/23
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/20/23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 08/04/23